Read this company snapshot
Daily valuation snapshot
Rein Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $0.79
- Market capitalization (USD)
- $68,496,023.41
- Price / earnings (TTM)
- Not reported
- Price / book
- 1.24
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RNTX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research RNTX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing RNTX with another company.
| Daily close (USD) | $0.79 |
| Market capitalization (USD) | $68,496,023.41 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.24 |
No matching rows. Clear the filter to see all records.
Read RNTX's valuation metrics
Company size
Rein Therapeutics, Inc. Common Stock's recorded market capitalization is $68,496,023.41. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
RNTX's recorded price-to-book ratio is 1.24. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Rein Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about RNTX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow RNTX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.